Company Encyclopedia
View More
name
Applied Therapeutics
APLT.US
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.
1.902 T
APLT.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking310/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-680.47%E
    • Profit Margin-1813.80%E
    • Gross Margin-860.10%E
  • Growth ScoreB
    • Revenue YoY571.70%A
    • Net Profit YoY90.32%A
    • Total Assets YoY-67.74%E
    • Net Assets YoY-109.52%E
  • Cash ScoreB
    • Cash Flow Margin-5.51%D
    • OCF YoY571.70%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio101.63%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    19:48 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT

    Class Action Attorney Juan Monteverde with Monteverde & Associates PC is investigating mergers involving Alexander & Baldwin, Dolly Varden Silver Corporation, Destination XL Group, and Applied Therapeutics. Shareholders of these companies are expected to receive specific compensations under the proposed transactions. Monteverde & Associates PC is recognized for recovering millions for shareholders and is a top firm in securities class action services.

    prnewswire·
    US
    APLT
    -45.92%
    US
    DXLG
    -26.92%
    prnewswire·
    US
    APLT
    -45.92%
    US
    DXLG
    -26.92%

    12 Health Care Stocks Moving In Friday's Intraday Session

    During Friday's intraday session, cbdMD (AMEX:YCBD) stock surged by 104.4%, while Canopy Growth (NASDAQ:CGC) rose 37.16%. Climb Bio (NASDAQ:CLYM) and Basel Medical Group (NASDAQ:BMGL) also saw significant gains. Conversely, Applied Therapeutics (NASDAQ:APLT) shares plummeted 44.2%, and Milestone Pharmaceuticals (NASDAQ:MIST) fell 37.69%. Other notable decliners included Tenaya Therapeutics (NASDAQ:TNYA) and WORK Medical Tech Gr (NASDAQ:WOK).

    benzinga_article·
    US
    CGC
    +53.98%
    US
    BMGL
    +30.92%
    US
    MIST
    -18.31%
    benzinga_article·
    US
    CGC
    +53.98%
    US
    BMGL
    +30.92%
    US
    MIST
    -18.31%

    APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders

    Halper Sadeh LLC is investigating the fairness of Applied Therapeutics, Inc.'s sale to Cycle Group Holdings Limited. The firm is assessing if the sale price and terms are fair to shareholders and if the board violated securities laws or fiduciary duties. Shareholders are urged to contact the firm for legal rights and options. Halper Sadeh LLC may seek increased consideration or additional disclosures for shareholders.

    MorningStar·
    US
    APLT
    -45.92%
    MorningStar·
    US
    APLT
    -45.92%

    BUZZ-Applied Therapeutics plunges after UK's Cycle Group to buy co

    Rare diseases drug developer Applied Therapeutics’shares slump 35.5% to $0.14 premarketCo said on Thursday UK-based Cycle Group will acquire all outstanding shares for $0.088 per share in cash, plus a contingent value right (CVR) The offer represents a 60% of discount to APLT’s last close of $0.22, though shareholders could receive additional payments (CVR) if specific future milestones are metThe transaction is expected to close in the first quarter of 2026Up to last close, stock down 74.7% YTD

    Reuters·
    US
    APLT
    -45.92%
    Reuters·
    US
    APLT
    -45.92%

    Cycle Pharmaceuticals to Acquire Applied Therapeutics | APLT Stock News

    Cycle Pharmaceuticals to acquire Applied Therapeutics, a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, targets CNS rare metabolic diseases. The acquisition includes a tender offer for Applied's shares at $0.088 per share plus contingent value rights (CVR) for potential additional payments. The transaction is expected to close in Q1 2026, subject to customary conditions. Applied issued a promissory note to Cycle for up to $8.5 million to fund working capital. The Applied Board of Directors unanimously approved the merger.

    StockTitan·
    US
    APLT
    -45.92%
    StockTitan·
    US
    APLT
    -45.92%
    © 2025 Longbridge｜Disclaimer